Raising the bar for randomized trials involving artificial intelligence: the SPIRIT-artificial intelligence and CONSORT-artificial intelligence guidelines
Taylor, Matthew Liu, Xiaoxuan Denniston, Alastair Esteva, Andre Ko, Justin Daneshjou, Roxana Chan, An-Wen
Taylor, Matthew
Liu, Xiaoxuan
Denniston, Alastair
Esteva, Andre
Ko, Justin
Daneshjou, Roxana
Chan, An-Wen
Citations
Altmetric:
Affiliation
University of Birmingham; Health Data Research UK; University Hospitals Birmingham NHS Foundation Trust; Moorfields Eye Hospital NHS Foundation Trust; UCL Institute of Ophthalmology; Salesforce AI Research; Stanford University School of Medicine; University of Toronto
Other Contributors
Publication date
2021-03-22
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Artificial intelligence (AI)-based applications have the potential to improve the quality and efficiency of patient care in dermatology. Unique challenges in the development and validation of these technologies may limit their generalizability and real-world applicability. Before the widespread adoption of AI interventions, randomized trials should be conducted to evaluate their efficacy, safety, and cost effectiveness in clinical settings. The recent Standard Protocol Items: Recommendations for Interventional Trials-AI extension and Consolidated Standards of Reporting Trials-AI extension guidelines provide recommendations for reporting the methods and results of trials involving AI interventions. High-quality trials will provide gold standard evidence to support the adoption of AI for the benefit of patient care.
Citation
Taylor M, Liu X, Denniston A, Esteva A, Ko J, Daneshjou R, Chan AW; SPIRIT-AI and CONSORT-AI Working Group. Raising the Bar for Randomized Trials Involving Artificial Intelligence: The SPIRIT-Artificial Intelligence and CONSORT-Artificial Intelligence Guidelines. J Invest Dermatol. 2021 Sep;141(9):2109-2111. doi: 10.1016/j.jid.2021.02.744. Epub 2021 Mar 22
Type
Article